AccessibilityHelpAbout Us
CSL logo

CSL(ASX) CSL

Market CapA$84.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1994)+38,123%
5 Year-38%
1 Year-9%
1 Month+7%
A$175.59
-1.11%
-1.97Today
CSL last closing stock price
MetricPriceDate
Last closeAUD 175.592026-09-18
CSL stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.08%AUD 167.102026-09-11
1 month+6.84%AUD 164.342026-08-19
3 month+52.92%AUD 114.832026-06-19
Year to date+4.35%AUD 168.262025-12-31
1 year-9.16%AUD 193.302025-09-18
3 year-29.35%AUD 248.552023-09-19
5 year-38.32%AUD 284.662021-09-17
Since inception+38,123.21%AUD 0.461994-06-02

CSL Financials at a Glance

Market Cap

A$84.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$31.21B

Net Income (TTM)

$509.33M

EPS (TTM)

-A$7.60

P/E Ratio

-23.13

Dividend

A$4.05

Beta (Volatility)

-0.01 (Low)

Price

A$175.59

Volume

0

Open

A$177.70

Previous Close

A$175.59

Daily Range

A$174.39 - A$177.89

52-Week Range

A$90.00 - A$222.47

Estimated Earnings Date

Feb 9, 2027

CSL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CSL

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. With a strong international presence, CSL serves key markets including Australia, the United States, Germany, the United Kingdom, Switzerland, and China.

Products and Services
  • CSL Behring focuses on plasma-derived therapies and recombinant treatments
  • CSL Seqirus specializes in non-plasma biotherapeutic products and influenza solutions
  • Research and development in both plasma and non-plasma therapeutics
Growth Outlook
  • Revenue of USD 7.3 billion in the latest quarter indicates strong market demand
  • Operating income margin of 18.97% reflects efficient cost management
  • Continued investment in R&D supports long-term growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of USD 30.5 billion demonstrates consistent performance
  • Net income of USD -2.9 billion in the latest quarter highlights recent challenges
  • Dividend yield of 2.31% offers attractive returns for investors
CSL Limited is structured into two main operating segments: CSL Behring and CSL Seqirus. The company has a robust pipeline of products and a commitment to innovation, which positions it well for future growth. Despite recent challenges reflected in net income, the strong revenue figures and operating margins indicate resilience in the biopharmaceutical sector. The focus on research and development, alongside a solid dividend yield, makes CSL Limited an intriguing option for potential investors looking to enter the biotechnology industry.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29,000

CEO

Gordon Naylor, MBA, CPA

Website

www.csl.com.au

Headquarters

Melbourne, VIC 3000, AU

CSL Financials

Key Financial Metrics (TTM)

Gross Margin

47.76%

Operating Margin

25.57%

Net Income Margin

-16.06%

Return on Equity

-15.12%

Return on Capital

15.96%

Return on Assets

-7.52%

Earnings Yield

-4.32%

Dividend Yield

2.31%

Payout Ratio

-53.84%

Stock Overview

Market Cap

A$84.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

479.88M

Volume

0

Avg. Volume

1.54M

Financials (TTM)

Gross Profit

$15.16B

Operating Income

$7.40B

EBITDA

$10.30B

Operating Cash Flow

$7.11B

Capital Expenditure

-$1.29B

Free Cash Flow

$5.82B

Cash & ST Invst.

$1.51B

Total Debt

$10.89B

CSL Performance Analysis

CSL annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 19,583,635,41535.4%
20242024-06-30USD 22,414,647,29414.5%
20252025-06-30USD 23,825,295,9676.3%
20262026-06-30USD 23,166,275,923-2.8%
CSL sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3121.5%
Q42025-06-30-11.7%
Q22025-12-3116.3%
Q42026-06-30-13.4%
CSL annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 6.894.3%
20242024-06-30USD 8.3120.5%
20252025-06-30USD 9.5314.7%
20262026-06-30USD -7.90N/A
CSL sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31443.4%
Q42025-06-30-48.7%
Q22025-12-31-60.4%
Q42026-06-30-831.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$7.31B

+8.0%

Gross Profit

$3.24B

+5.3%

Gross Margin

44.39%

N/A

Market Cap

A$84.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.91M

N/A

Employees

29,000

N/A

Net Income

-$2.94B

-896.7%

EBITDA

$1.93B

-18.6%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$1.51B

-8.7%

Total Debt

$10.89B

-10.6%

Accounts Receivable

$3.35B

+26.9%

Inventory

$6.62B

+11.1%

Long Term Debt

$9.75B

-13.3%

Short Term Debt

$1.14B

+20.9%

Return on Assets

-7.52%

N/A

Return on Invested Capital

14.23%

N/A

Free Cash Flow

$1.76B

+53.1%

Operating Cash Flow

$2.09B

+22.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RMD.AXResMed Inc.
A$31.87-0.53%
NEU.AXNeuren Pharmaceuticals Limited
A$20.68+0.68%
CUV.AXClinuvel Pharmaceuticals Limited
A$8.37+2.57%
ADO.AXAnteoTech Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About CSL

What is the current price of CSL?

CSL is trading at A$175.59 per share.

What is the 52-week range for CSL?

Over the past 52 weeks, CSL has traded between A$90.00 and A$222.47.

How much debt does CSL have?

As of the most recent reporting period, CSL reported total debt of $15.73B.

How much cash does CSL have on hand?

CSL reported $2.18B in cash and cash equivalents in its most recent financial results.

What is CSL’s dividend yield?

CSL currently has a dividend yield of 2.31%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services